Oakland Southfield Physicians

OSP News

Updated Pneumococcal Vaccine Recommendations for Adults Aged ≥65 Years Old

Posted: 02/04/2020

Incidence of pneumococcal conjugate vaccine (PCV13) type disease has been reduced to historically low levels among adults aged ≥65 years through indirect effects from pediatric PCV13 use. Implementation of a PCV13 recommendation for all adults aged ≥65 years in 2014 has had minimal impact on PCV13 type disease at the population level in this age group.

However, PCV13 is a safe and effective vaccine that can reduce the risk for PCV13 type pneumonia among persons aged ≥65 years. Balancing this evidence and considering acceptability and feasibility concerns, in June 2019 ACIP voted to no longer routinely recommend PCV13 for all adults aged ≥65 years.

Instead, recommendation of PCV13 should be based on shared clinical decision-making for adults aged ≥65 years who do not have an immunocompromising condition, CSF leak, or cochlear implant.

Click here for more information from the CDC.

We value your privacy. We use cookies and other technologies to keep the web site reliable and secure, tailor your experience, and measure web site performance, as described in our Privacy Policy.


OSP Technical Support